|
COMPARED
TO SURGERY
|
THERASEED®
TREATMENT(Brachytherapy
with
Pd-103)2
|
SURGERY
(Radical Prostatectomy)
|
|
Incontinence
|
Less than 1% 1, 5
|
As high as 10% 4
|
|
Impotence
|
Approximately
10-15% 1, 7
|
Up to 79.6% 5
|
|
Length of procedure
|
Approximately 45
minutes
|
1-4 hours
|
|
Hospitalization
|
Rarely
|
3-5 days
|
|
Resume routine
activities
|
Within days
|
Approximately 8
weeks
|
|
COMPARED
TO IODINE SEEDS (Brachytherapy with I-125)
|
THERASEED®
TREATMENT(Brachytherapy
with
Pd-103)2
|
IODINE
SEEDS(Brachytherapy
with
I-125)2
|
|
Three-year
probability of freedom from long-term complications
|
Approximately 100%
3
|
Approximately 82% 3
|
|
Works 2-3 times
faster for better control of rapidly dividing cells
|
Yes
|
No
|
|
Duration of common
side effects
|
2-3 weeks
|
60-90 days
|
|
COMPARED
TO CRYOSURGERY
|
THERASEED®
TREATMENT(Brachytherapy
with
Pd-103)2
|
CRYOSURGERY
|
|
Independent studies
spanning 12 years prove effectiveness
|
Yes
|
No
|
|
Impotence
|
Approximately
10-15% 1, 7
|
Vast majority 8
|
|
Hospitalization
|
Rarely
|
1-2 night stay
|
|
COMPARED
TO EBRT/IMRT
|
THERASEED®
TREATMENT(Brachytherapy
with
Pd-103)2
|
EBRT/IMRT
|
|
Length of treatment
|
Approximately 45
minutes
|
5 days a week for
6-8 weeks
|
|
Independent studies
spanning 12 years prove effectiveness
|
Yes
|
For EBRT only; no
12-year studies for IMRT
|
[1] Sharkey J, Cantor A, Solc Z, Huff W, Chovnick SD, Behar RJ, Perez R,
Otheguy J, Rabinowitz R. Brachytherapy versus radical prostatectomy in patients
with clinically localized prostate cancer. Current Urology Reports.
2002;3:250-257.
[2] The most commonly reported side effects of prostate brachytherapy are
short-term urinary or obstructive symptoms within the first few weeks after the
implant procedure.
[3] Peschel RE, Chen Z, Roberts K, Nath R. Long-term complications with
prostate implants: iodine-125 vs. palladium-103. Radiation Oncology
Investigations. 1999;7(5):278-288.
[4] Peschel RE, Colberg JW. Surgery, brachytherapy, and external-beam
radiotherapy for early prostate cancer. Lancet Oncology. 2003;4:233-41.
[5] Potosky, AL, Legler J, Albertsen PC, Stanford JL, Gilliland FD, Hamilton
AS, Eley JW, Stephenson RA, Harlan LC. Health outcomes after prostatectomy or
radiotherapy for prostate cancer: results from the prostate cancer outcomes
study. Journal of the National Cancer Institute. 2000;92(19):1582-1592.
[6] The estimated rate of incontinence with brachytherapy is less than 1
percent in the absence of a prior transurethral resection of the prostate, and
less than 5 percent with a prior resection, according to Sharkey, et. al.
(refer to reference #1 above).
[7] The incidence of impotence is estimated to be 10 percent to 15 percent
depending on preoperative potency, when this information was available,
according to Sharkey, et. al. (refer to reference #1 above).
[8] Long JP, Bahn D, Lee F, Shinohara K, Chinn DO, Macaluso JN Jr. Five-year
retrospective, multi-institutional pooled analysis of cancer-related outcomes
after cryosurgical ablation of the prostate. Urology. 2001 Mar;57(3):518-23.
|
